Dr Andrew Sykes, Consultant Clinical Oncologist
Dr Andrew Sykes
Consultant Clinical Oncologist
Dr Andrew Sykes MBBCh MRCP FRCP
Consultant Clinical Oncologist
Dr Sykes is a Consultant Clinical Oncologist
Areas of expertise
- Non-surgical treatment of head and neck cancer
- Radiotherapy
- Electro-chemotherapy for skin cancer
- Oncology
- Chemotherapy
About Dr Andrew Sykes
GMC number: 3311907
Year qualified: 1989
Place of primary qualification: University of Birmingham
Dr Andrew Sykes is a consultant clinical oncologist at The Christie. He graduated in medicine from the University of Birmingham in 1989, before moving to Manchester to train in oncology. He gained his fellowship with the Royal College of Radiologists in 1996. Dr Sykes was appointed as a consultant at The Christie in 1997 and is currently the clinical director of the Department of Clinical Oncology.
Dr Sykes specialises in treating head and neck cancer with chemotherapy and radiotherapy. He also provides radiotherapy support for the melanoma team. Alongside his clinical work, he is actively involved in research, with a particular interest in radiotherapy and chemotherapy for head and neck cancer, and electro-chemotherapy.
Currently, Dr Sykes is the chairman of the Head and Neck Clinical Subgroup for the Greater Manchester & Cheshire Cancer Research Network. His areas of expertise include chemotherapy, radiotherapy, head and neck cancer, and skin cancer.
Areas of expertise
- Clinical oncology
- Head and neck Surgery
- Radiotherapy
- Chemotherapy
Professional memberships
Articles by Dr Andrew Sykes
Taxane, platinum and 5-fu prior to chemoradiotherapy benefits patients with stage iv neck node-positive head and neck cancer and a good performance status
Ep-1152: prospective evaluation of relationships between radiotherapy dose to masticatory apparatus and trismus
Ep-1165: imrt survival outcomes, late toxicities and endocrine dysfunction for nasopharyngeal carcinoma
Radiotherapy treatment of non-melanoma skin cancer: a survey of current uk practice and commentary
Evaluation of an automatic segmentation algorithm for definition of head and neck organs at risk
Automatic segmentation to define organs at risk (oars) for function sparing head and neck imrt
Conventional fractionation should not be the standard of care for t2 glottic cancer
Carotid dosimetry for t1 glottic cancer radiotherapy
